Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Halozyme Therapeutics, Inc. (HALO)

-NasdaqGS
7.57 Up 0.02(0.26%) Apr 17, 4:00PM EDT
Get the big picture on all your investments.
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingDec 31, 2013Sep 30, 2013Jun 30, 2013Mar 31, 2013
Total Revenue 12,499   16,013   14,454   11,834  
Cost of Revenue3,540  683  1,284  739  
Gross Profit 8,959   15,330   13,170   11,095  
Operating Expenses
Research Development20,925  25,689  27,991  22,034  
Selling General and Administrative9,357  8,135  7,300  7,556  
Non Recurring -   -   -   -  
Others -   -   -   -  
Total Operating Expenses -   -   -   -  
Operating Income or Loss (21,323) (18,494) (22,121) (18,496)
Income from Continuing Operations
Total Other Income/Expenses Net65  51  58  55  
Earnings Before Interest And Taxes(21,259)(18,442)(22,063)(18,441)
Interest Expense728  850  849  848  
Income Before Tax(21,986)(19,292)(22,912)(19,288)
Income Tax Expense -   -   -   -  
Minority Interest -   -   -   -  
Net Income From Continuing Ops(21,986)(19,292)(22,912)(19,288)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (21,986) (19,292) (22,912) (19,288)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (21,986) (19,292) (22,912) (19,288)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.